Policy Recommendations to Promote Prescription Drug Competition: A Position Paper From the American College of Physicians.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 32926798.
- Also identified by DOI 10.7326/M19-3773.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The prescription drug market in the United States relies on competition to keep prices reasonable. Although many policies have been implemented to spur competition and decrease costs for patients, these policies may be outdated and should be redesigned and updated to achieve success in the current prescription drug market. In this paper, the American College of Physicians (ACP) proposes that new policies should be implemented to prevent market manipulation, help lower-cost alternatives make it to the market faster, and ensure a robust and competitive market for generic and biosimilar drugs. The ACP believes these changes will have a meaningful effect on patients without shifting costs to other areas of the health care system.
Medical subject headings
- Economic Competition
- Health Policy
- Prescription Drugs